NYMC Faculty Publications

Foxa2 Rewires Ap-1 for Transcriptional Reprogramming and Lineage Plasticity in Prostate Cancer

Zifeng Wang, Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, 02125, USA.
Scott L. Townley, Flinders University, College of Medicine and Public Health, Flinders Health and Medical Research Institute, Bedford Park, SA, 5042, Australia.
Songqi Zhang, Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, 02125, USA.
Mingyu Liu, Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, 02125, USA.Follow
Muqing Li, Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, 02125, USA.
Maryam Labaf, Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, 02125, USA.
Susan Patalano, Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, 02125, USA.
Kavita Venkataramani, Department of Biology, University of Massachusetts Boston, Boston, MA, 02125, USA.
Kellee R. Siegfried, Department of Biology, University of Massachusetts Boston, Boston, MA, 02125, USA.
Jill A. Macoska, Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, 02125, USA.
Dong Han, Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, 02125, USA.
Shuai Gao, Department of Cell Biology and Anatomy, New York Medical College, Valhalla, New York, 10595, USA.
Gail P. Risbridger, Melbourne Urological Research Alliance, Biomedicine Discovery Institute, Monash University, Melbourne, VIC, 3800, Australia.
Renea A. Taylor, Melbourne Urological Research Alliance, Biomedicine Discovery Institute, Monash University, Melbourne, VIC, 3800, Australia.
Mitchell G. Lawrence, Melbourne Urological Research Alliance, Biomedicine Discovery Institute, Monash University, Melbourne, VIC, 3800, Australia.
Housheng Hansen He, Department of Medical Biophysics, University of Toronto, Toronto, ON, M5G1L7, Canada.
Luke A. Selth, Flinders University, College of Medicine and Public Health, Flinders Health and Medical Research Institute, Bedford Park, SA, 5042, Australia.
Changmeng Cai, Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, 02125, USA. changmeng.cai@umb.edu.

Author Type(s)

Faculty

DOI

10.1038/s41467-024-49234-9

Journal Title

Nature Communications

First Page

4914

Document Type

Article

Publication Date

6-8-2024

Department

Cell Biology and Anatomy

Abstract

FOXA family proteins act as pioneer factors by remodeling compact chromatin structures. FOXA1 is crucial for the chromatin binding of the androgen receptor (AR) in both normal prostate epithelial cells and the luminal subtype of prostate cancer (PCa). Recent studies have highlighted the emergence of FOXA2 as an adaptive response to AR signaling inhibition treatments. However, the role of the FOXA1 to FOXA2 transition in regulating cancer lineage plasticity remains unclear. Our study demonstrates that FOXA2 binds to distinct classes of developmental enhancers in multiple AR-independent PCa subtypes, with its binding depending on LSD1. Moreover, we reveal that FOXA2 collaborates with JUN at chromatin and promotes transcriptional reprogramming of AP-1 in lineage-plastic cancer cells, thereby facilitating cell state transitions to multiple lineages. Overall, our findings underscore the pivotal role of FOXA2 as a pan-plasticity driver that rewires AP-1 to induce the differential transcriptional reprogramming necessary for cancer cell lineage plasticity.

This document is currently not available here.

Share

COinS